Symbols

AMRN

Amarin·NASDAQ

--(--)

AMRN Profile

Amarin Corporation Plc

A biopharmaceutical company that develops and commercializes cardiovascular and lipid-focused therapeutics

Industry

Pharmaceutical

Established Date

03/01/1989

Listing Date

04/02/1993

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.amarincorp.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

8th Floor, One Central Plaza, 36 Dame Street, Dublin 2, Ireland

Business

Introduction

Amarin Corporation Plc was incorporated in the United Kingdom on March 1, 1989. The Company is a pharmaceutical company focused on the commercialization and development of therapies that improve cardiovascular or cardiovascular health and reduce cardiovascular risk. The company's commercialized product, VASCEPA, was first approved by the U.S., or the U.S., the Food and Drug Administration, or the U.S. FDA, as a dietary supplement to reduce triglyceride or TG levels in adults with severe (≥ 500 mg/dL) hypertriglyceridemia, or marine indications.